Imidazo[1,2-c]pyrimidin-5-amine | 1415729-03-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: Imidazo[1,2-c]pyrimidin-5-amine
• CAS: 1415729-03-1
• 化学式: C₆H₆N₄
• 分子量: 134.14
• InChiKey: DQSRDCXTESGYKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  氯乙醛 、 2,4-二氨基嘧啶 在 碳酸氢钠 作用下， 以 水 为溶剂， 反应 2.0h， 以25%的产率得到7-氨基咪唑并[1,2-A]嘧啶
  参考文献：
  名称：

  Heteroaryl urea inhibitors of fatty acid amide hydrolase: Structure–mutagenicity relationships for arylamine metabolites

  摘要：

  The structure-activity relationships for a series of heteroaryl urea inhibitors of fatty acid amide hydrolase (FAAH) are described. Members of this class of inhibitors have been shown to inactivate FAAH by covalent modification of an active site serine with subsequent release of an aromatic amine from the urea electrophile. Systematic Ames II testing guided the optimization of urea substituents by defining the structure-mutagenicity relationships for the released aromatic amine metabolites. Potent FAAH inhibitors were identified having heteroaryl amine leaving groups that were non-mutagenic in the Ames II assay. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.076

文献信息

• 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
  申请人：Arnold D. Lee

  公开号：US20060235031A1

  公开（公告）日：2006-10-19

  Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  公式如下的化合物及其药学上可接受的盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1的定义如下，能够抑制IGF-1R酶，适用于治疗和/或预防增生性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病以及中枢神经系统疾病和疾病。
• 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
  申请人：Arnold Lee D.

  公开号：US20090118499A1

  公开（公告）日：2009-05-07

  Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  该公式化合物及其药学上可接受的盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1的定义如下，可抑制IGF-1R酶，用于治疗和/或预防高增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病和中枢神经系统疾病和病症。
• 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP2168968A1

  公开（公告）日：2010-03-31

  Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  式 (I) 的化合物 及其药学上可接受的盐，其中 X1、X2、X3、X4、X5、X6、X7、R1 和 Q1 在此定义，抑制 IGF-1R 酶，可用于治疗和/或预防过度增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和病症、中枢神经系统疾病和病症。
• US7534797B2
  申请人：——

  公开号：US7534797B2

  公开（公告）日：2009-05-19
• US7820662B2
  申请人：——

  公开号：US7820662B2

  公开（公告）日：2010-10-26